Posted by Michael Wonder on 07 Oct 2019
Mereo BioPharma receives FDA fast track designation for navicixizumab for the treatment of heavily pre-treated ovarian cancer
7 October 2019 - Mereo BioPharma today announces that the U.S. FDA has granted fast track designation to navicixizumab for the treatment of high grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least 3 prior therapies and/or prior bevacizumab.
Navicixizumab is an anti-DLL4/VEGF bispecific antibody and one of two product candidates Mereo acquired through its April 2019 merger with OncoMed Pharmaceuticals.
Navicixizumab has completed a Phase 1a monotherapy study in patients with various types of refractory solid tumors and is currently being evaluated in an ongoing Phase 1b study in combination with paclitaxel in patients with advanced heavily pretreated ovarian cancer. In line with the Company’s strategy, a range of strategic partnering discussions have been initiated to provide additional funding for the navicixizumab program.
